FRZB: A Target Enabling Package

FRZB is a negative regulator of Wnt signalling with anti-oncogenic properties observed within some cancer types. The link to AD, as noted below, is three-fold: (1) as a regulator of Wnt signalling, (2) as an inhibitor of ADAM17 mediated proteolysis, and (3) due to its involvement in module 42 (M42), a module identified in deep proteomic investigation of AD case-controls, which is strongly associated with both cognition and pathological progression. The basic target enablement package (TEP) developed here will provide validated antibodies, purified protein, and a bioinformatics workup of the FRZB gene. The deployment of novel useful resources for the scientific community will hopefully advance investigations within the academic and pharmaceutical industries to better understand the role played by FRZB in AD, and its potential as a novel target against disease progression. The aim of this project is to produce TEP reagents to help further understand the biology of FRZB in Alzheimer’s disease.